- Home
- DEC vs JANX Comparison
DEC vs JANX Comparison
Compare DEC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | JANX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 975.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DEC | JANX |
|---|---|---|
| Price | $14.65 | $17.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $22.29 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 885.8K | 670.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | ★ 311.06 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,829,142,000.00 | $10,000,000.00 |
| Revenue This Year | $26.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.90 | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $12.33 | $12.12 |
| 52 Week High | $18.90 | $35.34 |
Technical Indicators
Market Signals| Indicator | DEC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 63.08 | 66.08 |
| Support Level | $14.39 | $13.13 |
| Resistance Level | $15.49 | $30.47 |
| Average True Range (ATR) | 0.43 | 0.57 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 81.11 | 95.37 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.